Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Investigators found that in melanomas in particular, interleukin-6 blockade seems to be effective in the management of immune-related adverse events from immune checkpoint inhibitors.

Case Study Highlights Therapeutic Potential of Tocilizumab in MOGAD With Cancer 

Pending positive results from an early-stage trial, a mid-stage study evaluating MyoPAXon’s effect on other targeted muscles and muscle function will be initiated.

FDA Clears IND Application for Myogenica’s MyoPAXon in Muscular Dystrophy

Treated patients demonstrated improvements on the Bayley-4 in cognition, communication, and motor function that exceeded those seen in natural history studies of Angelman syndrome.

Ionis to Advance ION582 in Phase 3 Studies of Angelman Syndrome Following Positive Open-Label Data

Videos

The president and CEO at Alzheon shared recent insights into neurodegenerative diseases that suggest a single toxic trigger may be responsible for conditions like Alzheimer disease, leading to potential early intervention and treatment strategies. [WATCH TIME: 10 minutes] 

Altering Alzheimer Care Landscape With New, Advanced Therapeutics: Martin Tolar, MD, PhD

The assistant professor at Hunter College talked about the approach of localization to prevent misdiagnoses of multiple sclerosis and ensure patients receive appropriate treatment. [WATCH TIME: 3 minutes]

Optimizing Localization in Multiple Sclerosis Diagnosis: Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN

, has been with the team since September 2022. Follow her on Twitter 

Patricia Clark, CNP, a nurse practitioner at the Cleveland Clinic, talked about a specialized program for hospitalized patients with Parkinson disease that aligns hospital protocols with home medication regimens to improve care.

A Comprehensive Program to Enhance Inpatient Care for Patients With Parkinson Disease

The neuroradiologist at Mayo Clinic discussed the categorization of biomarkers for Alzheimer disease, focusing on core biomarkers specific to the disease and those reflecting related pathologies. [WATCH TIME: 8 minutes] 

Categorizing Biomarker Criteria for Alzheimer Disease Diagnosis and Staging: Clifford R. Jack Jr., MD

, has been with the team since October 2019. Follow him on Twitter 

Benjamin Greenberg, MD, a pediatric neurologist at the University of Texas Southwestern Medical Center, provided commentary on a recently initiated online program dedicated to empowering those affected by rare neuroimmune disorders.

SRNA’s Educational Micro-Course: Building a Greater Understanding of Rare Neuroimmune Disorders

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

YouTube

Spotlight

ATMRD 2024

Secondary Symptoms of Parkinson Disease

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Slideshows

Does the atypical antipsychotic clozapine carry high risk for the development of drug-induced parkinsonism? What are DSM-5 criteria for the diagnosis of neuroleptic-induced parkinsonism? These questions and more in our quiz.

Clinical

SUP-22-NRD0184 - /clinical/movement-disorders

Quiz: Drug-Induced Parkinsonism